Cloud PR Wire

Author: Kathir J

  • Back-to-School Season Shines on Screen, 12th Anniversary New Beginning: Zeagoo Honors Authentic Expression with “Be Different, Be You”

    As the early autumn atmosphere deepens, the student demographic seeks wardrobe refresh options for the back-to-school season. Zeagoo stands out with its apparel that combines fashionable design and comfortable quality—its 2025 Autumn Print Sweater was featured on the “Back-To-School Must-Haves” segment of WGN9 Daytime Chicago on August 19th, receiving an authoritative recommendation from a lifestyle expert. Simultaneously, Zeagoo approaches its 12th anniversary celebration. Centered around the brand slogan “Be different, be you,” Zeagoo will launch dual initiatives—a celebrity collaboration styling guide and a pop-up store at American Dream mall—offering consumers new autumn/winter styling choices and an immersive shopping experience.

    Authoritative Recognition: Zeagoo Print Sweater Selected as a “Back-To-School Must-Have“

    A highly influential daytime program in the Chicago area, WGN9 Daytime Chicago focuses on practical lifestyle needs. For this “Back-To-School Must-Haves” feature, TV lifestyle and beauty expert Milly Almodovar, former Senior Beauty Editor of COSMOPOLITAN Latin , curated essential items to help parents and children transition smoothly into the school year, evaluating products based on practicality, style, and scene adaptability. The Zeagoo 2025 Autumn Print Sweater was successfully selected based on its multi-faceted strengths.

    The recommended Zeagoo Women’s 2025 Fall Crewneck Cropped Sweater is designed for autumn/winter scenarios, with key highlights directly addressing consumer needs:

    • Precise Sizing and Diverse Color Palette:Sizes correspond to US standards with standard fit. Multiple color options are available, supporting the flexible choice of “size up for a looser effect,” accommodating different body types and style preferences.
    • Soft, Stretchy Material:Crafted from a 50.7% Viscose , 28.6% Polyester, and 20.7% Nylon knit blend, it offers a soft handfeel and strong warmth. The stretch properties ensure wearing comfort, suitable for both early spring and autumn/winter seasons.
    • Stylish, Figure-Flattering Design:The classic crewneck and long sleeve combination features rib-knit cuffs and hem for a casual feel. The short, crop length helps elevate the waistline and outline the figure curve, balancing everyday casualness with fashionable expression.
    • High Versatility for Various Occasions:Can be paired with high-waisted pants, leggings, or skirts for a casual look, or layered over tank tops or under jackets and coats for added warmth. Suitable for multiple scenarios including campus life, daily outings, shopping, and dates. Also an excellent gift option.

    12th Anniversary Celebration Launch: Dual Initiatives Honor Consumers, Unlocking New Autumn/Winter Experiences

    Since its founding, Zeagoo has consistently adhered to the slogan “Be different, be you,” advocating for effortless comfort, self-expression, and the realization of self-worth, focusing on creating easy, everyday wear for mature women. In September 2025, Zeagoo will celebrate its 12th anniversary. Through dual interactive initiatives—”influencer collaboration + pop-up store”—the brand will express gratitude for consumer loyalty while conveying a more inclusive and innovative future vision.

    For this anniversary, Zeagoo will collaborate with a mystery celebrity to launch an autumn collaborative styling guide. Centered around the core concept of “effortless comfort” and incorporating 2025 autumn/winter trends, the guide will provide consumers with versatile styling solutions for multiple scenarios.

    On September 19th-20th, Zeagoo will partner with brands including EKOUAER, COOFANDY, Arshiner, and PINSPARK to create a collaborative pop-up store in the atrium of the American Dream mall in New Jersey. The event combines “product experience + interactive sessions”: consumers can touch fabrics and try on 2025 autumn/winter new arrivals on-site, experiencing the quality and fit of Zeagoo apparel firsthand. Simultaneously, engaging interactive sessions will allow for a deeper understanding of the brand philosophy, offering an immersive experience of Zeagoo’s fashionable appeal.

    Recommended Autumn/Winter Best-Sellers: Meeting Comfort and Style Needs for Multiple Scenarios

    Beyond the TV-featured print sweater, Zeagoo’s 2025 Autumn/Winter collection includes multiple best-selling items covering core categories like outerwear and tops, balancing warmth, style, and scene adaptability, making them essential for any autumn/winter wardrobe:

    • Women’s Zip Up Hoodies Oversized Fleece Long Tunic Sweatshirts: Focused on “comfort + versatility,” it uses stretch fleece fabric that is skin-friendly and breathable without feeling restrictive. The hood with drawstrings, full zip, and knee-length design allow it to be worn as a jacket or outer layer with various styling options. Large pockets and drawstring details are practical and stylish. Pairs well with leggings, jeans, or shorts, suitable for Y2K, casual, boyfriend, and other styles.
    • Women’s Autumn Long Sleeve Shirts Bussiness Casual Knit Pullover Sweater: Blends business and casual elements, suitable for wearing alone or layered. Features drop-shoulder design and a curved hem for a slimming, fitted look. Available with color-block stripes or in solid colors for a simple, stylish effect. Made from soft knit fabric with ribbed collar and cuffs for comfort and breathability. Multiple color options. Pairs effortlessly with jeans, casual pants, or dresses for commute, daily wear, or party occasions.

    Explore More Possibilities, Unlock a New Zeagoo Autumn/Winter Style Journey

    From authoritative back-to-school season recommendations to the dual online and offline surprises of the 12th-anniversary celebration, and the quality presentation of autumn/winter best-sellers, Zeagoo consistently centers on “Be different, be you,” providing consumers with apparel choices that merge comfort and style, empowering women to confidently navigate every life scenario.

    Starting now, consumers can follow Zeagoo’s official channels (official website, Amazon flagship store, social media accounts) for information on purchasing back-to-school season items, details regarding the 12th-anniversary pop-up store, and the latest updates on the influencer collaborative styling guide. Unlock new autumn/winter styling inspiration and embrace every moment of life with confidence and ease.

    For more information, please visit the Zeagoo website and Amazon storefront, or connect with Zeagoo on Facebook and Instagram.

    Zeagoo

    Charlotte Liu

    pr@zeagoo.com

    New York, US

    https://zeagoo.com

  • Poolbetx Token (PBX) – The World’s First Crypto i-Gaming Digital Chip

    New York, NY – 28/08/2025 – (SeaPRwire) – As part of its launch, Poolbetx (https://poolbetx.com) proudly introduces its Token (PBX), a stable crypto coin designed as a digital igaming chip for the Poolbetx ecosystem.

    • Built on TON Blockchain: PBX runs on the highly scalable TON blockchain, ensuring speed, low fees, and reliability.
    • Global Accessibility: PBX can be accessed and traded across all major DEX pools including DeDust.io and Ston.fi.
    • Wallet Integration: Customers can easily buy, exchange, or cash out PBX tokens directly through Telegram Wallet and TON Hub Wallet, available on the Apple App Store and Google Play Store.
    • Borderless & Jurisdiction-Free: PBX enables seamless global usage, allowing Poolbetx players to withdraw, play, and transact without jurisdictional restrictions – a world-first innovation in crypto igaming platforms.

    “PBX is more than a token – it’s a bridge between our global customers and the Poolbetx ecosystem,” said a Poolbetx spokesperson. “By making PBX accessible on everyday apps like Telegram and Tonhub, we’re ensuring anyone, anywhere, can join Poolbetx with ease.”

    With PBX, Poolbetx not only provides premium i- games but also a financial infrastructure that redefines global access to entertainment.

    Related Links

    Telegram: https://t.me/poolbetx

    PBX on DeDust: https://dedust.io/

    PBX on Stonfi: https://ston.fi/

    Media contact

    Brand: Poolbetx

    Contact: media team

    Email: support@poolbetx.com

    Website: https://poolbetx.com

  • T-RIZE and Republic Launch ‘Vision 60’ to Expand Institutional Access to Tokenized Real Estate

    New York, NY – 27/08/2025 – (SeaPRwire) – T-RIZE Group, a global fintech firm offering institutional-grade tokenization infrastructure, is launching Vision 60 by Ste-Rose, a $24.2 million, 60-unit energy-efficient residential development in Laval, Québec. This project is part of a 500+ unit new construction deal with T-RIZE Group, valued at $200 million. Tokenized by T-RIZE, the offering is being launched through a strategic collaboration with Republic, one of the world’s leading regulated investment platforms with over 3 million users, $3 billion in deployed capital, and more than 2,500 ventures backed. Accredited investors will be able to participate using both fiat and cryptocurrency.

    Pipeline Execution in Motion

    Vision 60 by Ste-Rose follows Vision 87 by Champfleury, an 87-unit, $23 million tokenized offering that forms part of a separate $300 million, 956-unit residential development. Together, these offerings reflect the ongoing execution of T-RIZE’s multi-billion-dollar pipeline, applying a scalable, compliant framework for bringing real-world assets onchain.

    T-RIZE leads tokenization, including asset digitization, legal structuring, and smart contract deployment. Republic’s affiliate broker-dealer, OpenDeal Broker LLC , Member FINRA & SiPC, oversees investor onboarding and distribution under Regulation D.

    Token-Powered Infrastructure

    Vision 60 will be deployed on an EVM-compatible blockchain such as Base or Avalanche, two leading infrastructures supporting institutional adoption of real-world assets. Base, incubated by Coinbase, enables low-cost execution, robust security, and seamless integration with Ethereum and capital markets ecosystems, offering a strong foundation for tokenized financial products. Avalanche delivers high-performance infrastructure with flexible tooling, supporting regulatory alignment and scalable deployment of institutional tokenization use cases.

    The $RIZE utility token anchors the T-RIZE ecosystem. It is used to access and pay for tokenization services—including onboarding, structuring, and listing—while also unlocking vetted investment opportunities, enabling decentralized governance, and supporting ecosystem growth. With 30% of supply allocated to governance and incentives, $RIZE is listed on tier-1 venues like Kraken and Revolut.

    Built with Institutional-Grade Standards

    Vision 60 is supported by a network of third-party experts and institutions:

    ● Ekitas – Legal and tax structuring

    ● CBRE – Independent project appraisal

    ● BDO – Return and cash flow projections

    ● Intact Insurance – Performance bond underwriting

    ● MA2D – Lead developer

    ● Concept Habitation Duo Inc. – Property manager

    ● Republic – Regulated global investment platform

    T-RIZE also operates as a validator and RWA issuer on the Canton Network, a privacy-first blockchain used by institutions such as Goldman Sachs, Broadridge, and Cumberland, where over $2 trillion in monthly transactions are settled and more than $4 trillion in digital assets are safeguarded. This positions T-RIZE at the intersection of regulated finance and onchain innovation.

    “Tokenized real estate is no longer a concept—it’s entering its institutional growth phase,” said Madani Boukalba, CEO of T-RIZE Group. “Vision 60 is a real-world proof point of how scalable, compliant infrastructure unlocks global access to tokenized real estate—setting the stage for broader institutional adoption.”

    About Republic

    Headquartered in New York City, Republic is a global financial firm operating a network of retail-focused investment platforms and an enterprise digital advisory arm. With a deep track record of legal and technical innovation, Republic is known for providing access to new asset classes to investors of all types. Backed by Valor Equity Partners, Galaxy Interactive, HOF Capital, AngelList and other leading institutions, Republic boasts a global portfolio of over 2,000 companies and a community of nearly three million members in over 150 countries. More than $3 billion has been deployed through investment platforms, funds, and firms within the Republic family of companies with operations established in the US, the UK, EU, the UAE and South Korea. All broker-dealer related securities activity is conducted by OpenDeal Broker LLC, an affiliate of OpenDeal Inc. a registered broker-dealer, and member of FINRA | SiPC, located at 149 5th Avenue, 10th FL, New York, 10010 please check our background on FINRA’s BrokerCheck and Form CRS here.

    For additional information, visit https://republic.com/

    About T-RIZE Group

    Founded in 2022, T-RIZE is an institutional tokenization platform onboarding a multi-billion-dollar pipeline of real estate, structured financial products, and AI Energy Offset Reserve Notes. The T-RIZE platform transforms these assets into programmable digital

    instruments that unlock liquidity, lower capital costs, and enhance underwriting and risk modelling while protecting sensitive data through privacy-preserving AI. At its core, the RIZE token powers tokenization services, connects institutions to vetted investments and AI-driven infrastructure, and supports governance and incentive programs across the ecosystem.

    For more information, visit www.T-RIZE.io or contact:

    Press Inquiries: press@T-RIZE.io

    Head Office: 1155 René-Lévesque West, Suite 2500, Montreal, QC H3B 3X7, Canada Toronto Office: 130 King Street West, Suite 1900, Toronto, ON M5X 1E3, Canada

  • The Launch Press Conference of the 6th Lushan International Romance Film Week Held, Activating a New Business Model of “Movie and Tourism Integration”

    Beijing, China – On August 21, the Launch Press Conference of the 6th Lushan International Romance Film Week, themed “Green Wild Love Letter, Cinematic Lushan”, was held in Beijing. As a cultural brand carefully crafted by Lushan City, the Lushan International Love Film Week leverages the world cultural heritage of Lushan and its position as a landmark of Chinese Love Film culture, making it an important window to showcase the natural and cultural charm of Lushan. This year’s Film Week, themed “Fall in Love with Films”, will feature classic love films, immersive cultural and tourism experiences, and various other activities to promote deep integration between films and tourism, empowering tourism consumption and industrial revitalization through movie IP.

    Mountains and waters convey emotions, representing the ultimate romance unique to the Chinese people. Since its inception in 2020, the Lushan International Love Film Week has been held for five consecutive years, successfully integrating Lushan’s natural beauty and cultural heritage into cinematic art. It has explored the “Lushan Path” of transforming cultural resources into economic momentum and elevating local brands into international symbols. This year, marking the 120th anniversary of Chinese cinema, the 6th Lushan International Romance Film Week continues the theme of the 5th edition, “Lushan, Your Pillar of Love”, and innovatively launches the “Fall in Love with Films” sweet project, offering Chinese cinema a timeless romantic tribute.

    At the launch press conference, the Film Week Ambassador Chen Jianbin and Jiang Qinqin interacted remotely, sending beautiful blessings to all those who believe in love, yearn for love, and are currently in love, drawing inspiration from Lushan’s majestic grandeur and its towering waterfalls. “Fall in Love with Films” ambassador Li Xiaomeng voiced over a classic scene from the film “Romance on Lushan Mountain”, recreating the emotionally stirring love story. The group Shuimunianhua performed the theme song “I’m Waiting for You in Lushan”, marking the sparkling opening of this love-themed cinematic journey.

    During the Film Week, Lushan will present three major highlight activities centered around the theme “Fall in Love with Films”, including an all-encompassing immersive film-tourism experience, high-level exchanges between filmmakers and the tourism industry, as well as a magnificent celebration and heartfelt interactions. The “New Century Top Ten Love Films Recommendation” event, supported by the Chinese Film Critics Society, along with the “2024 Annual Love Film Main Creative Honors”, will also be officially announced during the event.

    As another successful example of CMG’s deepened central-local collaboration and co-creation model, this year’s Lushan International Love Film Festival will fully leverage the communication strengths of national media and the resource advantages of local industries. It aims to further integrate film culture with regional characteristics, solidify the festival’s brand identity as the “Lushan, Your Pillar of Love” – a phrase increasingly rooted in public awareness – and strengthen its systematic and long-term catalytic effect on related industries. The event continues to develop into a top-tier romantic film celebration in China with growing international influence.

    This year’s event will be fully showcased on  China Media Group’s Mobile, the new media platform of CMG. Compared to previous years, China Media Group’s Mobile will provide richer content formats and communication channels for the Lushan International Love Film Festival. Leveraging the resources of a national-level new media platform, it will innovatively launch special activities such as opening-day live streams and experience vlogs during the festival, while also initiating online topics and trending discussions on social media. These efforts will not only enable the scenic romance of Lushan to reach a wider audience through the cloud but also foster emotional resonance across the internet around the theme “Fall in Love with Films”.

    From September 5 to 11, let’s meet at the 6th Lushan International Romance Film Week, to experience the screen romance amidst the mist, to savor the enchanting scenery both on and off camera, and to witness Lushan, a landmark of love culture, in its innovative practices and vibrant charm.

  • COOFANDY Men’s Shirt Receives CNN Underscored Recommendation, Officially Launches 2025 Autumn/Winter New Collection

    COOFANDY, a leader in men’s fashion, proudly announces that its Men’s Casual Button-Down Shirt has been selected as a 2025 Editor’s Pick by CNN Underscored, CNN’s product recommendation source.

    About the CNN Recognition

    The COOFANDY Men’s Casual Button-Down Shirt was highlighted by CNN in their “Editor’s Favorite Products” for June 2025. This recognition underscores the men’s shirt‘s exceptional quality, style, and value, affirming its status as a modern menswear essential.

    The review from CNN Underscored regarding this men’s casual button-down shirt states: “I love it when someone compliments me on a shirt I’m wearing and I get to respond: ‘Thanks! I got it on Amazon for, like, 20 bucks.’ That’s the case with this COOFANDY button-down, which is exceptionally comfortable and lightweight, yet still polished enough to wear to the office or out for a night on the town. I’ve had a few of these men‘s shirts for years, but they became even more indispensable during this record-breaking NYC heat wave.”– Mike Andronico

    You can read the full feature highlighted by CNN

    COOFANDY Autumn/Winter Collection Now Available, Including Stylist Collaboration

    Building on the CNN Underscored recommendation, COOFANDY has launched its new Autumn/Winter collection, now available for purchase on Amazon. The collection features a variety of styles designed to elevate seasonal wardrobes, including an exclusive collection curated in collaboration with renowned stylist Britt Theodora.

    Outfit Recommendations:

    Men’s Plaid Button-Down Flannel Shirt: Crafted from soft and thick cotton flannel fabric, this shirt offers a warm and comfortable touch with excellent warmth retention, making it an essential piece for building layered looks.

    Men’s Mock Neck Long Sleeve Shirt: Its unique diamond pattern enhances the overall texture and sophistication, adding rich visual layers to the outfit whether worn open or buttoned.

    Men’s Casual Elastic Drawstring Trousers: Paired with these simple twill casual pants, the upper body’s patterns and textures are perfectly balanced, creating a well-proportioned look that is both refined and fashionable.

    This season’s Autumn/Winter outfit from COOFANDY masterfully blends classic checks, utilitarian practicality, and modern tailoring to create an urban sophisticate look that combines style with warmth. The core of this ensemble lies in its exceptional **layering** capabilities and **versatility**; each piece can harmoniously coordinate with others or stand alone, easily adapting to the changeable autumn and winter climate and various social occasions.

    COOFANDY Flannel Featured Series

    The artisanal flannel men‘s shirts from the COOFANDY Flannel Series are more than just COOFANDY products; they are a cornerstone of the brand’s identity and a testament to its commitment to comfort, quality, and timeless style. The iconic flannel shirt collection is meticulously crafted from premium brushed cotton fabric, offering an incredibly soft touch and exceptional insulation against the cold. Each shirt features both classic and contemporary patterns, from traditional buffalo checks and tartans to modern, subtle tonal plaids, ensuring a design for every preference.

    Beyond their signature look, these men‘s shirts are designed for versatility and durability. Attention to detail is evident in the reinforced stitching, sturdy buttons, and thoughtful fit, allowing for easy layering. Whether worn as a standalone statement piece on a crisp autumn day or as a cozy mid-layer under a jacket for winter adventures, COOFANDY’s flannels deliver unparalleled comfort and rugged reliability, season after season.

    About COOFANDY

    COOFANDY is an international brand dedicated to meeting the dressing needs of modern men. Adhering to the “Dress the Journey” philosophy, it is committed to providing men with high-quality, stylish, and cost-effective clothing options at every stage of life, accompanying them on their growth journey and exploring diverse styles.

    For more information, please visit the COOFANDY website and Amazon storefront, or connect with COOFANDY on Facebook and Instagram.

    COOFANDY

    Charlotte Liu

    pr@coofandy.com

    New York, US

    https://coofandy.com

  • CGTN: 60 years on, how China’s Xizang achieves all-round progress in development, prosperity

    On the 60th anniversary of the founding of China’s Xizang Autonomous Region, CGTN published an article highlighting the region’s remarkable social and economic progress over the past six decades. The article emphasizes that Xizang, under President Xi Jinping’s leadership, has experienced unprecedented development and significant changes, with people enjoying increasingly tangible benefits.

    A grand gathering to celebrate the 60th anniversary of the founding of China’s Xizang Autonomous Region was held at the Potala Palace square in Lhasa on Thursday morning. Chinese President Xi Jinping joined around 20,000 local officials and people from all ethnic groups and all walks of life in the celebration.

    Dressed in festive attire, crowds waved red flags and flower bouquets, extending a warm welcome to President Xi, who was also presented with a hada – a scarf-like white silk used by people in Xizang to show respect and blessings.

    In a historic first for both the Party and the country, Xi led a central delegation to attend events marking the anniversary of the founding of the Xizang Autonomous Region as general secretary of the Communist Party of China (CPC) Central Committee, Chinese president and chairman of the Central Military Commission.

    Hearing work reports from the CPC Xizang regional committee and the regional government on Wednesday, Xi urged efforts to build a modern socialist new Xizang that is united, prosperous, civilized, harmonious and beautiful, calling on the region to advance high-quality development and continue to make solid efforts on the four main tasks of ensuring stability, facilitating development, protecting the eco-environment and strengthening the borders.

    Profound changes

    Kala Village of Xizang’s Nyingchi City was once an impoverished and isolated village, where logging, herding and growing highland barley were the main means of livelihood for the villagers.

    The turning point came in 2015 when a paired assistance team from Guangdong Province, tasked with aiding Xizang, took full advantage of the village’s cultural and tourism resources, identifying tourism featuring peach blossom as the breakthrough point to accelerate the village’s development.

    In 1998, villagers earned 2,000 yuan (around $276) from tourism, while in 2024, Kala Village welcomed over 110,000 visitors savoring the peach blossoms, with tourism revenue topping 3.7 million yuan. From relying solely on its natural resources to developing a thriving “peach blossom economy,” Kala Village’s vibrant practice of rural revitalization has made it a microcosm of Xizang’s broader progress.

    Since 2012, Xi has elevated Xizang’s strategic position to a new level, and presided over two central symposiums on work in Xizang, defining guiding principles, objectives and tasks in the new era. To date, Xizang has experienced a period of unprecedented development and momentous change, with people enjoying more and more tangible benefits. It showcases the remarkable success of China’s system of regional ethnic autonomy.

    Figures highlight Xizang’s historic progress in economic and social development. The region’s GDP hit 276.5 billion yuan in 2024, 154 times that of 1965, reaching an average annual growth rate of 8.9 percent. The per capita disposable income of urban and rural residents increased from 456 yuan and 108 yuan respectively in 1965 to 55,444 yuan and 21,578 yuan in 2024.

    Notably, the region has eliminated millennia-old absolute poverty and realized a moderately prosperous society in all respects alongside the rest of the nation. The transformation of people’s daily lives is evident – moving from buckets of water, oil lamps and dirt paths to running tap water, electric lights and paved roads. Xizang residents now have access to services such as the internet, rail and air travel.

    Governing Xizang, ensuring its stability and promoting its prosperity must begin with maintaining political and social stability, ethnic unity and amity among different religions, Xi pointed out during Wednesday’s meeting.

    Building a modern socialist new Xizang

    In addition to the peach blossom economy, Kala Village has also diversified its income sources through ways such as the introduction of fruit-picking gardens and organized planting and breeding projects, forging a path to prosperity that achieves a win-win result between ecological conservation and economic development.

    How to promote Xizang’s high-quality development? Xi pinpointed during Wednesday’s meeting: “Xizang needs to develop competitive plateau industries based on local conditions, with a particular focus on industries of agriculture and animal husbandry with local features, as well as the clean energy sector.”

    In recent years, the region has continued to enhance its distinctive and advantageous industries such as cultural tourism, agriculture and animal husbandry, digital technology and Tibetan medicine, and accelerated the cultivation of emerging industries such as plateau light industry.

    Green development is also a benefit to people’s livelihood. The region has always prioritized eco-environmental conservation and has become one of the world’s healthiest eco-environment regions.

    In Wednesday’s meeting, Xi called on the region to promote ecological conservation, and to make coordinated efforts to cut carbon emissions, reduce pollution, expand green development and pursue economic growth, so as to protect “the roof of the world” and “the water tower of Asia.”

    For more information, please click:

    https://news.cgtn.com/news/2025-08-21/How-China-s-Xizang-achieves-great-progress-in-development-prosperity-1G0MYtI6VSo/p.html

  • Best Synthetic Urine Brand for 2025: Upass Takes the Top Spot

    United States – [20-08-2025] – An independent review of the leading synthetic urine brands available in the United States has named Upass Synthetic Urine, manufactured by SafeguardLabs, as the Best Synthetic Urine Brand for 2025.

    The annual review, conducted by the Industrial Market Research Group, evaluated publicly available product specifications, official brand documentation, and third-party data to measure performance in four key categories: composition accuracy, format and usability, shelf life, and brand reliability. The 2025 analysis revealed measurable differences between top products, with Upass emerging as the market leader.

    Unmatched Realism in Composition Upass earned the highest marks for chemical accuracy and overall realism. According to the research, the formulation comes remarkably close to the composition of natural human urine, with precise balances of pH, specific gravity, creatinine, urea, uric acid, and additional trace elements. These parameters are critical to authenticity, and in Upass, they are matched to a degree that meets or exceeds calibration standards used in some professional testing laboratories.

    Laboratory-Grade Calibration Quality In addition to its accurate chemical profile, Upass reproduces the visual and physical characteristics of fresh human urine, including realistic foam formation, clarity, and natural coloration. Its subtle scent and foam behavior further reinforce its authenticity. The review noted that certain laboratories employ Upass for equipment calibration purposes—an endorsement that underscores its scientific precision.

    Shelf Life and Packaging Innovation Upass also scored strongly for packaging and shelf stability. The product is shipped in a sealed, contamination-resistant container that protects it from environmental changes, extending its shelf life compared to competing brands. Its ready-to-use format, combined with clear storage guidelines, contributes to consistent quality over time.

    Brand Reliability and History SafeguardLabs, the manufacturer of Upass, has maintained a steady presence in the synthetic urine market for over a decade. Known for consistent quality control and adherence to published specifications, the company’s reliability was a key factor in securing the top ranking. The review found no significant discrepancies between Upass’s claimed specifications and independent measurements.

    A Clear Market Leader for 2025 “With measurable performance advantages in composition accuracy, realism, and packaging, Upass sets the current standard for synthetic urine products,” said Mark Wiseberg, lead analyst at Industrial Market Research Group. “Its chemical fidelity to natural human urine and proven shelf stability make it the clear choice for both consumers and industry professionals.”

    The full review includes comparative analysis of other leading brands in the market, detailing how they ranked in each test category. These findings are available upon request for industry stakeholders, laboratories, and regulatory bodies seeking further technical detail.

     

    Media Contact
    Company Name: Industrial Market Research Group
    Contact Person: Mark Wiseberg
    Email: Media@marketresearchgroup.com
    Country: United States
    Website: https://safeguardlabs.com/

  • CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

    SHENZHEN, CHINA – On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.

    The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.

    According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.

    “New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum

    At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.

    To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.

    Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.

    Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.

    CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.

     

    Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth

    According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.

    Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.

    In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.

    Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.

     

    About CMS

    CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

     

    CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

     

    CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.

     

    CMS Disclaimer and Forward-Looking Statements

    This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

     

    This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

     

    Media Contact

    Brand: China Medical System Holdings Ltd.

    Contact: CMS Investor Relations

    Email: ir@cms.net.cn

    Website: https://web.cms.net.cn/en/home/

    Source: China Medical System Holdings Ltd.

  • CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

    SHENZHEN, CHINA – On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.

    The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.

    According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.

    “New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum

    At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.

    To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.

    Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.

    Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.

    CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.

     

    Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth

    According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.

    Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.

    In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.

    Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.

     

    About CMS

    CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

     

    CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

     

    CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.

     

    CMS Disclaimer and Forward-Looking Statements

    This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

     

    This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

     

    Media Contact

    Brand: China Medical System Holdings Ltd.

    Contact: CMS Investor Relations

    Email: ir@cms.net.cn

    Website: https://web.cms.net.cn/en/home/

    Source: China Medical System Holdings Ltd.

  • CGTN: How China’s ‘two mountains’ concept is shaping global green development

    CGTN published an article exploring the significance of China’s “two mountains” concept, a green growth philosophy that is central to the country’s ecological efforts and serves as an inspiration for global sustainable development.

    Erik Solheim recalled that over a decade ago, he was too worried about smog in Beijing to even run outdoors. Today, the former executive director of the United Nations Environment Programme makes time for morning runs whenever he returns to the city.

    During a jog this year, Solheim noted that most vehicles on the road were “quiet, pollution-free, cost-effective” new energy vehicles, a visible transformation that reflects a deep shift in China’s green growth philosophy – one rooted in a concept articulated by President Xi Jinping: “Lucid waters and lush mountains are invaluable assets.”

    The “two mountains” concept, which literally means green mountains and clear waters are as valuable as mountains of gold and silver, has become a guiding principle for China’s ecological efforts and a source of inspiration for sustainable development worldwide.

    As President Xi has said, “Harmony between man and nature is a defining feature of Chinese modernization. China is a steadfast actor and major contributor in promoting global green development.”

    A philosophy that guides real change

    First put forward in 2005 during Xi’s visit to Yucun Village in east China’s Zhejiang Province, the “two mountains” concept has transformed from a local slogan into a cornerstone of China’s national strategy.

    Today, China leads the world in renewable energy deployment. It had installed nearly 1.889 billion kilowatts of total renewable capacity by the end of 2024, including approximately 887 million kilowatts of solar, 521 million kilowatts of wind and 436 million kilowatts of hydropower, which accounted for 56 percent of the nation’s total power capacity and supplied about 35 percent of its electricity generation.

    The “two mountains” concept has sparked interest well beyond China. A global opinion poll released by CGTN, covering 24,515 respondents from 48 countries, showed that 81.6 percent of global respondents believe the concept has broken the traditional “polluting first and cleaning up later” model of growth.

    Clifford Cobb, a leading ecological economist in the United States, has closely followed China’s environmental path. He believes the idea presents a new model of development.

    “Over the past 20 years, China has proven that it’s possible to protect nature while generating economic value,” Cobb said. “It’s a win-win vision the world can learn from.”

    Promoting international cooperation for a greener future

    China’s green development vision is helping power global cooperation. A vivid example can be found on the vast steppes of northern Kazakhstan’s Akmola Region, where renewable energy is transforming the local economy.

    Engineer Khasabay Kinlosan is part of that change. Every day, he maintains more than 40 wind turbines that are part of a major Belt and Road cooperation project between China and Kazakhstan. These turbines produce over 800 million kilowatt-hours of clean electricity annually, cutting carbon emissions by 650,000 tonnes.

    As the Belt and Road Initiative moves into a new stage of high-quality development, the “two mountains” philosophy is finding growing resonance abroad.

    Almas Chukin, a prominent Kazakh economist, says the concept struck a chord with him. “China has become a leader in solar and wind power, and it is addressing global challenges such as climate change through action, not just words,” he said.

    China’s commitment to a shared green future goes far beyond Central Asia. It has supported low-carbon development and ecological capacity building in more than 100 developing countries, particularly small island nations and African states.

    Through multilateral platforms like the South-South Climate Cooperation Initiative and the Belt and Road’s Green Development Partnership, China is exporting not only technologies but also growth models and sustainability know-how.

    Its contributions to global biodiversity are equally notable. In 2022, China hosted COP15 of the Convention on Biological Diversity, helping broker the landmark Kunming-Montreal Global Biodiversity Framework. UN officials noted that the agreement’s success owes much to China’s long-standing emphasis on a “whole-of-society” approach to environmental governance.

    “President Xi’s ecological civilization thought holds great theoretical value and has also proven highly effective in practice,” said Eliason Kaganga, a Tanzanian scholar focused on protecting Lake Victoria. “China’s solutions – especially those that empower local people – are bringing lasting benefits to African countries and communities.”

    https://news.cgtn.com/news/2025-08-16/How-China-s-two-mountains-concept-shapes-global-green-development-1FSGt4l2H9C/p.html